AstraZeneca buys US drug firm for £293m

 
Suzie Neuwirth

FTSE 100-listed AstraZeneca today announced that it has agreed to buy US cardiovascular drug company Omthera Pharmaceuticals for $443m (£293m).

The pharmaceuticals giant said that the deal is expected to close in the third quarter of 2013.

“This is an exciting acquisition that clearly complements our existing portfolio in cardiovascular and metabolic disease, one of our core therapy areas,” said Pascal Soriot, chief executive of AstraZeneca.